Bluebird Will Be Early Adopter Of EU Adaptive Pathways Pilot
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm has agreements to submit its gene therapy for beta thalassemia for accelerated approval with FDA and for conditional approval in Europe, under a new pilot process.